{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:47:51Z","timestamp":1788814071083,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Qatar National Library"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chronic myeloid leukemia (CML), while traditionally a disease of the elderly, has recently risen in incidence among younger patients. Hence, fertility concerns have emerged considering the disease process and treatments, especially with the current scarce and conflicting recommendations. This review explores the impact of CML treatments including the first-line tyrosine kinase inhibitors (TKIs) and other treatments on male fertility in chronic myeloid leukemia (CML) patients. The aim of this review was to compile the available evidence on male fertility to ultimately tailor treatment plans for male CML patients for whom fertility and future chances for conception pose a concern. The data available on the conventional and newer TKIs to address fertility concerns were reviewed, particularly the potential long- and short-term effects. Also, the possible side effects on subsequent generations were a crucial focus point of this review to reach a more comprehensive CML management approach. We found and compared the evidence on TKIs approved to treat CML. We also reported the effects of hydroxyurea, interferon, and transplantation, which are considered second-line treatments. Our findings suggest that these drugs might have an undiscovered effect on fertility. More research with larger sample sizes and longer follow-up periods is essential to solidify our understanding of these effects.<\/jats:p>","DOI":"10.3390\/cancers16040791","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T05:55:59Z","timestamp":1707976559000},"page":"791","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Male Fertility and Fatherhood in Chronic Myeloid Leukemia: Current Understanding and Future Perspectives"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-9888","authenticated-orcid":false,"given":"Ahmed Adel","family":"Elsabagh","sequence":"first","affiliation":[{"name":"College of Medicine, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2382-3021","authenticated-orcid":false,"given":"Maria","family":"Benkhadra","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care & Research, Hamad General Hospital, Doha P.O. Box 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Elmakaty","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Elsayed","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1411-9462","authenticated-orcid":false,"given":"Basant","family":"Elsayed","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-4828","authenticated-orcid":false,"given":"Mohamed","family":"Elmarasi","sequence":"additional","affiliation":[{"name":"College of Medicine, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2984-0252","authenticated-orcid":false,"given":"Mohammad","family":"Abutineh","sequence":"additional","affiliation":[{"name":"Hematology Section, Medical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha P.O. Box 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel Mohammad","family":"Qasem","sequence":"additional","affiliation":[{"name":"Hematology Section, Medical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha P.O. Box 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elrazi","family":"Ali","sequence":"additional","affiliation":[{"name":"One Brooklyn Health, Interfaith Medical Center, Brooklyn, NY 11213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassin","sequence":"additional","affiliation":[{"name":"Hematology Section, Medical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha P.O. Box 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Minciacchi, V.R., Kumar, R., and Krause, D.S. (2021). Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. Cells, 10.","DOI":"10.3390\/cells10010117"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","article-title":"Management of pregnant chronic myeloid leukemia patients","volume":"9","author":"Abruzzese","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/hematology.2019000050","article-title":"Meeting the needs of CML patients in resource-poor countries","volume":"2019","author":"Malhotra","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2022-171160","article-title":"Chronic Myeloid Leukemia in Adolescents and Youngadults: Clinicopathological Variables and Outcomes","volume":"140","author":"Abdulla","year":"2022","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Elhadary, M., Elsabagh, A.A., Ferih, K., Elsayed, B., Elshoeibi, A.M., Kaddoura, R., Akiki, S., Ahmed, K., and Yassin, M. (2023). Applications of Machine Learning in Chronic Myeloid Leukemia. Diagnostics, 13.","DOI":"10.3390\/diagnostics13071330"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","article-title":"Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials","volume":"16","author":"Yun","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1025392","DOI":"10.3389\/fmed.2022.1025392","article-title":"A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia","volume":"9","author":"Ahmed","year":"2022","journal-title":"Front. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1163137","DOI":"10.3389\/fmed.2023.1163137","article-title":"A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"10","author":"Kaddoura","year":"2023","journal-title":"Front. Med."},{"key":"ref_12","first-page":"7787","article-title":"Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence","volume":"25","author":"Ciftciler","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-022-03446-1","article-title":"Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: Differences and similarities","volume":"117","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/cpt.813","article-title":"Tyrosine Kinase Inhibitors and Male Reproductive Health","volume":"102","author":"Ramstein","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_15","first-page":"42","article-title":"WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors","volume":"37","author":"Kuzu","year":"2020","journal-title":"Turk. J. Haematol."},{"key":"ref_16","first-page":"95","article-title":"Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?","volume":"10","author":"Morsi","year":"2016","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_17","unstructured":"Ali, E., Soliman, A., De Sanctis, V., Nussbaumer, D., and Yassin, M. (2021). Priapism in Patients with Chronic Myeloid Leukemia (CML): A Systematic Review. Acta Biomed., 92."},{"key":"ref_18","first-page":"S127","article-title":"Therapeutic progress and comparative aspects in chronic myelogenous leukemia (CML): Interferon alpha vs. hydroxyurea vs. busulfan and expression of MMTV-related endogenous retroviral sequences in CML. German CML Study Group","volume":"8","author":"Hehlmann","year":"1994","journal-title":"Leukemia"},{"key":"ref_19","first-page":"ix\u2013III1","article-title":"NTP-CERHR monograph on the potential human reproductive and developmental effects of hydroxyurea","volume":"vii\u2013viii, v","author":"Program","year":"2008","journal-title":"NTP Cerhr. Mon."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3390\/ijerph6031124","article-title":"Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints","volume":"6","author":"Jones","year":"2009","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1445-5994.2006.01290.x","article-title":"Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease","volume":"37","author":"Grigg","year":"2007","journal-title":"Intern. Med. J."},{"key":"ref_22","first-page":"1216","article-title":"Azoospermia in a patient with sickle cell disease treated with hydroxyurea","volume":"85","author":"Garozzo","year":"2000","journal-title":"Haematologica"},{"key":"ref_23","unstructured":"Soliman, A.T., Alaaraj, N., and Yassin, M. (2021). The Effects of Treatment with Blood Transfusion, Iron Chelation and Hydroxyurea on Puberty, Growth and Spermatogenesis in Sickle Cell Disease (SCD): A short update. Acta Biomed., 92."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: A retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML","volume":"94","author":"Talpaz","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10428194.2016.1201571","article-title":"Pregnancy: Part of life in chronic myelogenous leukemia","volume":"58","author":"Law","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1634\/theoncologist.2017-0381","article-title":"Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-\u03b1","volume":"23","author":"Gazdaru","year":"2018","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","article-title":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","volume":"84","author":"Trevisan","year":"2023","journal-title":"Ann. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2605.2007.00755.x","article-title":"Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat","volume":"30","author":"Nurmio","year":"2007","journal-title":"Int. J. Androl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJM200411113512024","article-title":"Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome","volume":"351","author":"Seshadri","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0253-7613.83107","article-title":"Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino mice","volume":"43","author":"Prasad","year":"2011","journal-title":"Indian J. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1556\/2060.2023.00192","article-title":"Dasatinib and quercetin increase testosterone and sperm concentration in mice","volume":"110","author":"Garcia","year":"2023","journal-title":"Physiol. Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.apjtm.2015.06.001","article-title":"Effect of PDGF-Rb antagonist imatinib on endometrial injury repairing in mouse model","volume":"8","author":"Wang","year":"2015","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/REP-20-0548","article-title":"Deleterious reproductive effects of nilotinib in mouse model","volume":"161","author":"Ozkavukcu","year":"2021","journal-title":"Reproduction"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"IJH26","DOI":"10.2217\/ijh-2020-0004","article-title":"Pregnancy outcomes in patients treated with bosutinib","volume":"9","author":"Cortes","year":"2020","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11523-017-0521-6","article-title":"Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase","volume":"12","author":"Chang","year":"2017","journal-title":"Target Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1120.e15","DOI":"10.1016\/j.fertnstert.2010.08.060","article-title":"Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty","volume":"95","author":"Mariani","year":"2011","journal-title":"Fertil. Steril."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3109\/10428194.2013.811240","article-title":"Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib","volume":"55","author":"Gentile","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00404-010-1501-6","article-title":"Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib","volume":"283","author":"Oweini","year":"2011","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00277-023-05280-9","article-title":"Fertility and pregnancy in chronic myeloid leukemia: Real-world experience from an Indian tertiary care institution","volume":"102","author":"Chethan","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1083\/jcb.149.5.1019","article-title":"Leydig cell loss and spermatogenic arrest in platelet-derived growth factor (PDGF)-A-deficient mice","volume":"149","author":"Gnessi","year":"2000","journal-title":"J. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1210\/er.2010-0004","article-title":"Role of platelet-derived growth factors in the testis","volume":"31","author":"Basciani","year":"2010","journal-title":"Endocr. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood.V120.21.1688.1688","article-title":"Effects of Tyrosine Kinase Inhibitors On Spermatogenesis and Pituitary Gonadal Axis in Males with Chronic Myeloid Leukemia","volume":"120","author":"Yassin","year":"2012","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2017.77.2574","article-title":"Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy","volume":"36","author":"Berman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_48","first-page":"e33407","article-title":"The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients with Chronic Myeloid Leukemia: A Mixed-Method Study","volume":"15","author":"Ali","year":"2023","journal-title":"Cureus"},{"key":"ref_49","first-page":"980","article-title":"Fertility and disease outcomes in patients with chronic myeloid leukemia","volume":"40","author":"Dou","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J. Pediatr."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.leukres.2007.07.022","article-title":"Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases","volume":"32","author":"Breccia","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2141.2007.06542.x","article-title":"Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy","volume":"137","author":"Ramasamy","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2040620720966120","DOI":"10.1177\/2040620720966120","article-title":"Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: Opinion, evidence, and recommendations","volume":"11","author":"Abruzzese","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(01)05482-4","article-title":"Pregnancy outcomes after peripheral blood or bone marrow transplantation: A retrospective survey","volume":"358","author":"Salooja","year":"2001","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.beha.2009.09.008","article-title":"CML in pregnancy and childhood","volume":"22","author":"Apperley","year":"2009","journal-title":"Best Prac. Res. Clin. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"963223","DOI":"10.3389\/fonc.2022.963223","article-title":"Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia","volume":"12","author":"Schleicher","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/791\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:00:07Z","timestamp":1760104807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":58,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16040791"],"URL":"https:\/\/doi.org\/10.3390\/cancers16040791","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}